Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer ( PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...

COVID questions answered. I just participated in a classic disease spreader: We had a family reunion with over 30 people. One ...

The Department of Health and Human Services will cancel contracts and pull funding for some vaccines that are being developed ...

The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...